Stryker Appoints Spencer Stiles as CEO; Kevin Lobo to Serve as Chair

Stryker Corp. has announced a planned leadership transition. The company named current President and Chief Operating Officer Spencer Stiles as its next CEO, effective January 1, 2027. Stiles will succeed Kevin Lobo, who has led the medical technology company since 2012 and will transition to the role of Executive Chair of the Board of Directors.

"Having worked alongside Spencer for many years, I have seen firsthand the qualities that define his leadership," said Kevin Lobo, CEO of Stryker, in a statement regarding the transition.

A Decade of Growth

The appointment marks the end of a 14-year tenure for Lobo, who took the helm in October 2012. Under his leadership, the Kalamazoo-based company saw financial growth, with annual net sales climbing from $8.7 billion at the start of his tenure to over $26 billion in 2026, according to a report from Investing.com.

Operational Continuity

Stiles is an internal candidate currently serving as the company's President and COO. His elevation to the CEO role is part of a long-term succession plan intended to maintain operational stability as the firm navigates the medical device market. As of October 9, 2026, Stryker Corp. (SYK) shares were trading at $277.33.

Implications for Stakeholders

For shareholders and employees, the shift from Lobo to Stiles represents a continuation of the company's existing strategic direction. By moving Lobo into the Executive Chair position, Stryker intends to retain his institutional knowledge while transitioning day-to-day management responsibilities to Stiles. This structure is common among large-cap medical device manufacturers that seek to balance new leadership perspectives with the stability required for long-term research and development cycles.